Gujarat Themis Biosyn Limited — Others, 01-08-2025: Cessation

Gujarat Themis Biosyn's Board has approved the financial results for the quarter, reporting a Net Profit of INR 9.06 Cr on a total income of INR 36.15 Cr. A record date of September 5, 2025, was set for the dividend for FY25. The company will not proceed with its proposed merger with Themis Medicare Limited, choosing instead to focus on its core fermentation-based pharmaceutical intermediates business. Operationally, a new API plant at Vapi began commercial production on May 4, 2025, aiming to support forward integration and strengthen export markets. The Board also appointed Mr. Nihar Parikh as an Additional Non-Executive Independent Director, replacing Mr. Siddharth Kusumgar, effective August 1, 2025. Mr. Parikh will join key committees.